Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

l be presented at an upcoming medical meeting, along with additional efficacy data from the 240 mg/day and lower dose groups. Final selection of the Phase 3 dose will be made following completion of data analyses.

"We are pleased to have reached another development milestone in our prostate cancer program by successfully completing enrollment in our Phase 1-2 clinical trial in castration-resistant prostate cancer patients with limited treatment options," said Lynn Seely, M.D., chief medical officer of Medivation. "We look forward to presenting additional data from this trial and to advancing this program into Phase 3 development in 2009, as we have previously guided."

About Prostate Cancer and MDV3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to de
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Newswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NU...ng products for minimally disruptive surgical trea...ent of Michael J. Lambert as Executive Vice Presid...r 9, 2009. The Company also announced several oth...el will be an excellent complement to the NuVasive...
(Date:11/6/2009)...ov. 6 With his proposed health car...sights on cutting name-brand prescription drug cos...to the "Part D" coverage gap, universally known as...otential cost-cutting and feel it,s a promising st...werful lobbyists want a revised program that compl...
(Date:11/6/2009)...wswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CY...financial results for the second quarter ended Oct...2010 on Wednesday, November 18, 2009 at 5:00 PM ES...discuss those results on Thursday, November 19, 20... Quarter Results Conference Call Instructions ,...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Biochemical on switch could solve protein purification challenge 10485 1Biochemical on switch could solve protein purification challenge 10485 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3Study reveals an increase in long term antidepressant drug use 59950 1
...h, MIAMI and PALM BEACH, Fla., Sept. 2 September...Knife Centers of Miami and,Palm Beach announce a r...out surgery and long treatment courses of radiatio...er affecting men in the US., Morse CyberKnife CEO...at are diagnosed early on, CyberKnife radiosurgery...
...ensity and Secondary Efficacy ...all and Webcast Wednesday, September 3rd at ...GO, Sept. 2 Neurocrine Biosciences,Inc. (Nasdaq: ...cy results,from its third Phase II clinical trial ...nadotropin-Releasing Hormone (GnRH) receptor antag...
Other Medicine Technology:Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6
(Date:11/9/2009)... Doctor house calls now available in New ... New York, NY (PRWEB) November 9, ...an, will now offer routine house calls to resident...able to request a house call by calling the offi...bregman.com . The convenience of being able to see...
(Date:11/9/2009)... Leading U.S. air ambulance company now t...AMI accreditation and Department of Defense approv...EB) November 9, 2009 -- AirMed International, the ...y it has earned full accreditation from the Europe...tuttgart, Germany, based non-profit association of...
(Date:11/9/2009)...Nov. 9 Davis Bregman , a pain m...alls to residents of Manhattan in New York City. ...by calling the office at 212-918-1629 or sending a...e of being able to see the doctor in the less stre...is new way of seeing most patients. The service w...
(Date:11/8/2009)..., Nov. 8 Jon O,Brien, p...wing statement about the passage of HR 3962: ,...can voters a lot about core values. We in the proc...eking to overcome the struggles ordinary Americans...many cannot afford basic healthcare or have to cho...
(Date:11/8/2009)... UCW Academy of Health holds open house a...ria, BC (Vocus) November 8, 2009 -- UCW Academy of...n British Columbia’s health care industry to... November 25, 2009. , ,UCW Academy of Health, whi..., nursing and social services, designs its program...
Breaking Medicine News(10 mins):Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:College Invites Public to Explore Career Options in Health Care 2
...er phobia, study finds , , MONDAY, May 5 (...ptions about their children,s fever and overtreat ...y shows. , Parents, ethnicity may also play a role... fix it, so every pediatrician must have the fever...
...ncer patients who have a prior history of mood and...periencing posttraumatic stress disorder following...y of 74 breast cancer patients at the Ohio State U...e as likely as breast cancer patients without the ...
...or Edward G.,Rendell today urged the Senate to imm...PA ABC) for the uninsured now that an analysis sho... "The financial analysis released today by the Gov...le health insurance,through PA ABC; and continue t...
...n Promotes Cancer Screenings and Early ... the help of Texas Oncology this,Mother,s Day, giv...t that,will last: good health. Texas Oncology make...l way to stay healthy., The Mother,s Day Screenin...
...atter of debate, experts say , , MONDAY, M...emiums increase, so do the rates of Caesarean sect...mall snapshot of the association, drawing on data ... higher malpractice rates boost the C-section rate...
...y of Texas Medical Branch at Galveston researchers...new weapon against respiratory syncytial virus, th...he United States. , In an effort to find an effec...uses to replicate, or copy itself, within cells. B...
Other Medicine News:Health News:Ethnicity Plays Role in Parents' Treatment of Childhood Fever 2Health News:Anxiety, mood disorders put cancer patients at risk for PTSD 2Health News:PA Governor Says Financial Analysis Shows Nothing Stands in Way of Senate Action to Help Pennsylvania's Uninsured 2Health News:Texas Oncology Reminds Women 'You're the Best, Get the Tests' 2Health News:Texas Oncology Reminds Women 'You're the Best, Get the Tests' 3Health News:Malpractice Premiums, Rate of C-Sections Rise Together 2Health News:Malpractice Premiums, Rate of C-Sections Rise Together 3Health News:New agent strikes at respiratory syncytial virus replication 2
Single Tantalum Clip (50 Style)
Silicone Strip (41 Style)
Charles Silicone Tire (282 Style)
Asymmetrical Silicone Tire (276 Style)
Medicine Products: